Swiss auto-immunity specialist Polyneuron Pharmaceuticals AG has received CHF14m from HBM Healthcare Investments.
Dutch Amarna Therapeutics has appointed Dr Steen Klysner. The new CEO has been active in the biotech industry for more than 30 years
Polish Mabion SA and Australian Vaxine Pty Ltd to develop Covax-19
Japanese dermatology specialist Maruho Co. Ltd and drug discovery firm 4SC AG have terminated their development agreement related to 4SC’s blockers of Kv1.3 ion channels, which are required for maintenance of activation of T cells. 4SC reacquired all rights to the preclinical development programme, which was aimed at specifically calm down chronically stimulated memory T-cell populations with Kv1.3highIK-1low phenotype as a strategy to treat autoimmune diseases.
The companies gave no reasons for the end of their collaboration. 4SCs CEO Jason Loveridge, however, said that "a good deal of progress has been made" in the three years of the collaboration. Under the terminated colloaboration, 4SC had granted Maruho the exclusive worldwide rights to develop and commercialise two classes of these blockers in exchange for US-$103 in milestones plus royalties.
RNA therapeutics specialist MiNA Therapeutics plc has secured £23m in a Series A financing to push development its first-in-class small activating RNA (saRNA) candidates.
In October Juan Carlos Jaramillo will take over the business from Wolfgang Bender as new Chief Medical Officer and member of the Valneva Management Board.
Nine CEOs of COVID-19 vaccines have assured that safety of vaccinated individuals remains their top priority in development of the first COVID-19 vaccines.
Andrew Topen is the new Chairman of the European Association for Bioindustries EuropaBio.
The European Investment Bank has lend up to €10m to Polish microbial diagnostics specialist Scope Fluidics AS.
Roche has announced to launch a SARS-CoV-2 point-of-care antigen test this month co-developed with SD Biosensor Inc. (South Korea).